OZGEN, U., S. O. SENER, Karel ŠMEJKAL, Jiří VÁCLAVÍK, D. F. SENOL, Orhan I ERDOGAN, Emil ŠVAJDLENKA, A. C. GOREN a Milan ŽEMLIČKA. Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds. TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES. CANKAYA-ANKARA: TURKISH PHARMACISTS ASSOC, 2020, roč. 17, č. 5, s. 528-534. ISSN 1304-530X. Dostupné z: https://dx.doi.org/10.4274/tjps.galenos.2019.71598.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds
Autoři OZGEN, U., S. O. SENER, Karel ŠMEJKAL (203 Česká republika, domácí), Jiří VÁCLAVÍK (203 Česká republika, domácí), D. F. SENOL, Orhan I ERDOGAN, Emil ŠVAJDLENKA (203 Česká republika, domácí), A. C. GOREN a Milan ŽEMLIČKA (203 Česká republika, domácí).
Vydání TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, CANKAYA-ANKARA, TURKISH PHARMACISTS ASSOC, 2020, 1304-530X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Turecko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Kód RIV RIV/00216224:14160/20:00118239
Organizační jednotka Farmaceutická fakulta
Doi http://dx.doi.org/10.4274/tjps.galenos.2019.71598
UT WoS 000585327200011
Klíčová slova anglicky Anticholinesterase; HPLC; isolation; Lysimachia; tyrosinase
Štítky rivok, ÚPL
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Hana Hurtová, učo 244985. Změněno: 24. 2. 2021 08:03.
Anotace
Objectives: The scope of the present study was to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase and tyrosinase (TYR) inhibitory and antioxidant activity of Lysimachia verticillaris (LV), and to isolate the major compounds considering the most active fraction. Materials and Methods: The methanol extract (ME) of LV and the chloroform, ethyl acetate (EtOAC), and aqueous fractions obtained from it were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and TYR inhibitory and antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from the active EtOAC fraction by semi-preparative high performance liquid chromatography. The structures of the compounds were elucidated by several spectroscopic methods. Results: Marked AChE inhibitory activity was observed in the EtOAC fraction (6337 +/- 1.74%), BChE inhibitory activity in the ME and EtOAC fraction (85.84 +/- 3.01% and 83.82 +/- 3.93%), total phenol content in the EtOAC fraction (261.59 +/- 3.95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515.54 +/- 2.80 mg equivalent of quercetin/1 g of extract), and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and ferric-reducing antioxidant power values in the aqueous and EtOAC fractions (92.54 +/- 0.67%, 92.11 +/- 0.30%; 2.318 +/- 0.054, 2.224 +/- 0.091, respectively). Accordingly, the isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-alpha-rhamnopyranoside, quercetin 3-O-beta-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-alpha-rhamnopyranoside, respectively) were isolated from the active EtOAC fraction. Conclusion: LV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.
VytisknoutZobrazeno: 23. 7. 2024 21:19